Abstract
Mutations of the TP53 gene are the most common genetic alterations in human malignancies. Overexpression of the p53 protein has been reported in high frequencies in all types of skin cancer. To determine the role of TP53 in the pathogenesis of malignant melanoma, we investigated the expression of p53 in 12 cell lines and 145 primary and metastatic lesions by immuno-histochemistry, Overexpression of p53 was predominantly detected in the cytoplasm of the cells in 96 (66%) tumor and 12 (93%) cell lines. In contrast to findings in other tumor types, in melanomas immunoreac-tive cells were found in clusters or as scattered single cells. In primary melanomas, the frequency of p53 overexpression did not correlate with tumor thickness. Nucleotide sequencing of TP53 genes of 24 melanoma tumors/cell lines demonstrated point mutations in seven samples, all coding for mutant p53 protein species. The frequency of TP53 alterations of 20%-30% is lower than in other skin tumor types. Notably, immuno-histochemistry was not a suitable method to distinguish overexpression of wild-type p53 from mutant species, since cell lines/tumors with TP53 mutations did not show distinctive staining patterns. The mutation pattern in six out of seven lesions was similar to that caused by ultraviolet light damage. This finding may be regarded a further indication for a pathogenetic role of UV light damage in at least a subgroup of malignant melanomas.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Akslen LA, Morkve O (1992) Expression of p53 protein in cutaneous melanoma. Int J Cancer 52:13–16
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–220
Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, MacGeoch C, Spurr NK, Bartek J, Vojtesek B, Picksley SM, Lane DP (1992) Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340:259–263
Bartek J, Iggo R, Gannon JV, Lane DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899
Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature in a wide spectrum of human malignancies. Oncogene 6:1699–1703
Baudier J, Delphin C, Grunwald D, Khochbin S, Lawrence JJ (1992) Characterization of the tumour suppressor protein p53 as a protein kinase C substrate and a S100b binding protein. Proc Natl Acad Sci USA 89:11627–11631
Bhatia K, Goldschmits W, Gutierrez M, Gaidano G, Dalla-Favera R, Magrath I (1993) Hermi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J 7:951–956
Bishop JM (1987) The molecular genetics of cancer. Science 235:305–311
Brash DE, Ziegler JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J (1991) A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124–10128
Campbell C, Quinn AG, Ro YS, Angus B, Rees JL (1993a) p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 100:746–748
Campbell C, Quinn AG, Angus B, Rees JL (1993b) The relation between p53 mutations and p53 immunostaining in non-melanoma skin cancer. Br J Dermatol 129:235–241
Campo E, Calle-Martin O, Miquel R, Palacin A, Romero M, Fabregat V, Vives J, Cardesa A, Yague J (1991) Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 51:4436–4442
Castresana JS, Rubjo MP, Vazquez JJ, Idoate M, Sober AJ, Seizinger BR, Barnhill RL (1993) Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55:562–565
Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J (1992) p53 mutations in breast cancer. Cancer Res 52:5291–5298
Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofolini P, Dalla Plam P, Barbaresch M (1993) p53 protein expression in nevi and melanomas. Arch Dermatol 129:739–743
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) p53 gain of function mutations. Nature Gen 4:42–45
Dockhorn-Dworniczack B, Yandell DW, Merritt V, Böcker W, Poremba C (1993) p53 mutation in malignant melanoma. 84rd annual meeting of the American Association of Cancer Research, Orlando. Proc Am Assoc Cancer Res 34:658
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215–221
Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602
Ginsberg D, Mechta F, Yaniv M, Oren M (1991a) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979–9983
Ginsberg D, Michael-Michalovitz D, Ginsberg D, Oren M (1991b) Induction of growth arrest by a temperature sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol Cell Biol 11: 582–585
Halevy O, Michalovitz D, Oren M (1990) Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250:113–116
Hall PA, Ray A, Lemoine NR, Midgley CA, Krauz T, Lane DP (1991) p53 immuno-staining is a marker of malignancy in diagnostic cytopathology. Lancet 338:513
Hall PA, McKee PH, Menage HP, Dover R, Lane DP (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203–207
Harvey D, Levine A J (1991) p53 alteration is a commmon event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev 5:2375–2385
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311
Klein G (1993) Genes that can antagonize tumor development. FASEB J 7:821–825
Lane DP (1992) p53 the guardian of the genome. Nature 358:15–16
Lassam NJ, From L, Kahn HJ (1993) Over-expression of p53 is a late event in the development of malignant melanoma. Cancer Res 53:2235–2238
Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453–456
Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasias. Science 254:1233–1238
Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689–1694
McGregor JM, Yu CCW, Levison DAL, MacDonald DM (1992) Aberrant expression of p53 tumour suppressor protein in malignant melanoma and dysplastic naevi. 22nd annual meeting of the European Society of Dermatological Research ESDR, London, p 166
Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane DP, Barnes DM (1992) Analysis of p53 expression in human tumours: an antibody raised against p53 expressed in E.coli. J Cell Sci 101:183–189
Miller HJ (1985) Mutagenic specificity of ultraviolet light. J Mol Biol 182:45–68
Milner J (1991) p53 in the normal control of cell proliferation. Curr Opin Cell Biol 3:282–286
Moles JP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Theillet C, Basset-Seguin N (1993) p53 gene mutations in human epithelial skin cancers. Oncogene 8:583 – 588
Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262–7266
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708
Oren M (1992) p53: the ultimate tumor suppressor gene? FASEB J 6:3169–3176
Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon-tumor-derived cell line. Proc Natl Acad Sci USA 89:4495–4499
Shaulski G, Ben-Zeev A, Rotter V (1990) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5:1707–1711
Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM (1993) The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325–332
Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum M, Cavenee WK, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355:846–847
Stephen CW, Lane DP(1992) Mutant conformation of p53: precise epitope mapping using a filamentous phage epitope library. J Mol Biol 225:577–583
Stretch JR, Gatter KC, Ralfkiaer E, Lane D, Harris AL (1991) Expression of mutant p53 in melanoma. Cancer Res 51:5976–5979
Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244
Volkenandt M, Schlegel U, Nanus DM, Albino AP (1991) Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 4:35–40
Vousden K (1993) Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 7:872–879
Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC (1993) Mutation and expression of the p53 gene in malignant melanoma cell lines. Int J Cancer 53:693–699
Weiss J, Cavenee WK, Herbst RA, Jung EG, Arden KC (1994) Point mutations and allelic loss in the TP53 locus of malignant melanomas. Arch Dermatol Res 286: 417–419
Yamamoto M, Takahashi H (1993) Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin. Virchows Arch [A] 422:127–132
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature 352:345–347
Zambetti GP, Levine AJ (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855–865
Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216–4220
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Weiss, J. et al. (1995). Mutation and Expression of TP53 in Malignant Melanomas. In: Garbe, C., Schmitz, S., Orfanos, C.E. (eds) Skin Cancer: Basic Science, Clinical Research and Treatment. Recent Results in Cancer Research, vol 139. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78771-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-78771-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78773-7
Online ISBN: 978-3-642-78771-3
eBook Packages: Springer Book Archive